dr. ritchie on immunological response to venetoclax/ibrutinib in r/r mcl
Published 4 years ago • 145 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:09
dr. ritchie on the immunologic impact of long-term venetoclax/ibrutinib in r/r mcl
-
1:28
dr. ritchie on immunological recovery with venetoclax and ibrutinib in mcl
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
3:06
durable responses to ibrutinib and venetoclax in r/r mcl: 3-year aim update
-
1:09
dr. goy discusses ibrutinib with venetoclax in mcl
-
2:06
the role of venetoclax in r/r mcl & options for patients who progress on venetoclax
-
1:01
dr. ritchie on the rationale of the aim trial in relapsed/refractory mantle cell lymphoma
-
1:13
dr. hamlin on early study of ibrutinib/buparlisib in mcl, fl, and dlbcl
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
1:22
dr. kaplan on the combination of ibrutinib and venetoclax in mcl
-
3:18
sympatico: safety and efficacy of ibrutinib plus venetoclax for r/r mcl
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
9:02
efficacy and future role of ibrutinib in cll and mcl
-
3:39
managing adverse events of ibrutinib in patients with mcl
-
0:48
real-world results in the uk for ibrutinib at first relapsed for mcl
-
1:46
btk inhibitors continue to improve survival in mantle cell lymphoma
-
4:59
ibrutinib in mcl: changing the treatment landscape
-
1:02
dr. tam on zanubrutinib vs ibrutinib research in mantle cell lymphoma
-
1:08
dr. tam on the toxicities of ibrutinib plus venetoclax in mcl